Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

38.37 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,965
Open 38.37
Bid (Size) 38.11 (24)
Ask (Size) 38.14 (24)
Prev. Close 38.37
Today's Range 38.37 - 38.37
52wk Range 33.67 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 3.76%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
Via Benzinga
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network

Performance

YTD
+2.29%
+2.29%
1 Month
-11.67%
-11.67%
3 Month
-1.21%
-1.21%
6 Month
-6.09%
-6.09%
1 Year
+6.35%
+6.35%

More News

Read More
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via FinancialNewsMedia
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Via Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Via Benzinga
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
Via MarketBeat
Topics Economy
Exposures Interest Rates
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
From Alector, Inc.
Via GlobeNewswire
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
Via Benzinga
Exposures Product Safety
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
Via Benzinga
Exposures Product Safety
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
From GSK plc
Via Business Wire
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Via Investor's Business Daily
Topics Death
Exposures Death
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
Via Investor's Business Daily
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
Via Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
Via Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug
Via Benzinga
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.